ArticleBMC ophthalmology2022

Response to brolucizumab treatment for refractory serous pigment epithelial detachment secondary to polypoidal choroidal vasculopathy.

Seung Wan Nam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.